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Abstract
Background
Motor cortex stimulation (MCS) was introduced as a last-resort treatment for chronic neuro-
pathic pain. Over the years, MCS has been used for the treatment of various pain syn-
dromes but long-term follow-up is unknown.
Methods
This paper reports the results of MCS from 2005 until 2012 with a 3-year follow-up. Patients
who suffered from chronic neuropathic pain treated with MCS were studied. The analgesic
effect was determined as successful by decrease in pain-intensity on the visual analog
scale (VAS) of at least 40%. The modifications in drug regimens were monitored with use of
the medication quantification scale (MQS). Stimulation parameters and complications were
also noted. Interference of pain with quality of life (QoL), the Quality of Life Index (QLI), was
determined with use of a specific subset of questions from the MPQ-DLV score.
Results
Eighteen patients were included. Mean pre-operative VAS changed from 89.4 ± 11.2 to 53.1
± 25.0 after three years of follow-up (P < 0.0001). A successful outcome was achieved in
seven responders (38.9%). All patients in the responder group suffered from pain caused by
a central lesion. With regard to all the patients with central pain lesions (n = 10) and periph-
eral lesions (n = 8), a significant difference in response to MCS was noticed (P = 0.002).
MQS scores and QLI-scores diminished during the follow-up period (P = 0.210 and P =
0.007, respectively).
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Conclusion
MCS seems a promising therapeutic option for patients with refractory pain syndromes of
central origin.
Introduction
In the early 1990s, Tsubokawa and colleagues presented that chronic motor cortex stimulation
(MCS) was effective in treating thalamic pain syndromes[1]. Over the years, various reports in
which this last resort treatment was discussed were published and more indications for MCS
were introduced; see for reviews, Lima et al. and Fontaine et al.[2, 3]. The main indications for
MCS are [1] central post-stroke pain (including thalamus syndrome), [2] neuropathic orofacial
pain of various origins, [3] phantom limb pain, and [4] pain due to peripheral plexus avulsion
[3, 4]. It has recently been estimated that over 700 patients were treated with MCS worldwide,
using a variety of protocols[5]. Due to this heterogeneity, comparison of the results of MCS
remains difficult[5]. Next to the many success cases, other papers that discuss the lack of effi-
cacy of MCS have been published as well[6–8]. Nevertheless, the current literature suggests
that MCS holds promise for patients that suffer from specific conditions, such as trigeminal
neuropathic pain and post-stroke pain[9], although the exact mechanisms of MCS remain
matter of debate. One of the hypothesized mechanisms includes the activation of various inter-
neural circuits within the primary motor cortex, inducing an antidromic modulation of the
thalamacortical fibers[1, 10, 11]. With regard to this, different forms of stimulation have
shown to activate different neural circuits. Anodal stimulation seems to preferably activate the
corticospinal tract directly, whereas cathodal stimulation seems to stimulate the thalamocorti-
cal tracts and the corticospinal tract indirectly. The stimulation of thalamocortical tracts and
indirect stimulation of the corticospinal tract was observed to achieve the greatest pain relief
[11]. MCS has also been shown to activate different brain regions remote from the site of stim-
ulation. For example, the orbitofrontal cortex, the insula, the cingulate cortex, the putamen,
the thalamus and the PAG have all been observed as areas that are influenced by MCS[12, 13].
Next to these aforementioned mechanisms, the neurochemical effects of MCS has been inves-
tigated as well. For example, MCS is known to enhance the release of endogenous opioids in
pain-related circuits such as the periaquaductal grey and cingulate cortex[14]. Furthermore,
the density of opioid receptor binding in the brain predicts the clinical outcome of MCS[15].
It has also been postulated that the activation of both inhibitory (GABAergic) pathways and
excitatory (glutametergic) pathways[11, 16, 17] plays an important role in MCS. For instance,
an impaired intracortical inhibition, present in neuropathic pain patients, seems to be restored
after stimulation of the primary motor cortex. This indicates the involvement of the inhibitory
system[17]. Other studies proposed the involvement of the inhibitory system in thalamic mod-
ulation after MCS[18–22]. The excitatory pathways are also hypothesized to be involved as the
putamen releases dopamine after MCS as a result of activation of the glutametergic corticos-
triatal projections[23, 24]. The link between the analgesic effect of MCS and the glutamate N-
methyl-D-aspartate (NMDA) receptors has been established as well[25, 26], which could
explain the long-lasting analgesia that occurs after stimulation of the motor cortex[27]. Other
evidence from experimental models of neuropathic pain show that analgesia after electrical
stimulation originates from the rostroventral medulla as well as the descending serotoninergic
pathways, which shows involvement of the serotonergic system[28]. Next to the discussion
concerning suitable candidates and the influenced pathways, the efficacy of MCS seems to
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depend greatly on the appropriate positioning of the electrode over the cortical area of interest
and the applied stimulation parameters. Different shapes of the electrodes and settings of the
pulse generator are known to stimulate different neural structures and mechanisms in the
brain[11, 29]. This study aims to determine the efficacy of MCS by presenting the results of
MCS after a long-term follow-up of 3 years, using an assessment using changes in VAS scores,
the daily intake of pain medication and the changes in quality of life (QoL) scores.
Material and methods
Study protocol
In 2003, an observational study protocol was set up in the university medical centers of Nijme-
gen and Groningen, the Netherlands, in order to study the effects of MCS in patients that suf-
fered from chronic neuropathic pain[30]. Patients were included between 2005 and 2013 when
they suffered from chronic intractable neuropathic pain and reported high levels of pain
(VAS 5, measured three times daily during four days[31]). The diagnosis chronic neuro-
pathic pain was based primarily on the patient’s history and physical examination. Question-
naires based on the sensory descriptors and the quality of life have been developed to diagnose
chronic neuropathic pain. These instruments have been shown to be valid and reliable dis-
criminators of chronic neuropathic pain. In addition, the presence of weakness, allodynia or
hyperalgesia all favor a diagnosis of chronic neuropathic pain[32]. Furthermore, radiographic
imaging techniques performed less than three years before inclusion for MCS, a neuroanatom-
ical explanation that might contribute to the pain should be seen. Patients were selected by
anesthesiologist-pain specialists, neurosurgeons, and clinical psychologists. At intake, patients
were asked to fill-in 1)the McGill Pain Questionnaire; 2)the Symptom CheckList 90; 3)the
5-level Euro Quality of Life 5D version; 4) the Sickness Impact Profile 68 and; 5)to register
their daily medication intake using a medication journal. Quantitative sensory testing and an
extensive physical examination were carried out to assess and quantify sensory- and motor
function. Patients with severe, current psychological problems (e.g., depression, high anxiety)
or substance-abuse were excluded. Other exclusion criteria were the use of therapeutic antico-
agulants, cognitive and/or psychiatric disorders in the medical history, nociceptive pain, an
expected life expectancy less than 3 years due to other diseases (e.g., cancer), contra- indica-
tions for general anesthesia (e.g., severe cardio-pulmonary diseases), convulsive disorders and
the presence of other neuromodulation systems. All patients underwent preoperative somato-
sensory-evoked potential (SSEP) measurement to determine the integrity of the somatosen-
sory system in order to facilitate intra-operative neurophysiological monitoring. A MRI-scan
was used to determine any anatomical contra-indications (brain atrophy, pathological struc-
tures) for the operative procedure. All patients presented in this study had a follow up of three
years. Final diagnosis of patients was carried out in accordance with internationally renowned
guidelines[33, 34].
Surgical technique
The pre-operative fMRI was fused with the neuronavigation MRI. For this purpose, cortex sur-
face rendering technique was performed using the Stealthviz software (Medtronic Inc., Minne-
apolis, MN, USA) to visualize the cortical areas and determine the central sulcus and the motor
cortex, which then was marked on the skin by using neuronavigation. All patients were oper-
ated under general anesthesia without muscle relaxation. A small craniotomy (approximately
4 × 4 cm) was carried out over the central sulcus. An electrode was placed perpendicular to the
central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN,
USA). The central sulcus was identified using the phase reversal of the somatosensory evoked
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potential recorded with an eight-contact electrode strip during median nerve stimulation.
Consequently, monopolar anodal train-of-five stimulation was used to map motor function at
different locations in the precentral gyrus. Stimulation intensity was increased until a repro-
ducible motor evoked potential was found in the muscle of interest (e.g. m. flexor carpi radialis
or m. abductor pollicis brevis). Results from electrophysiological testing were taken together
with intraoperative neuronavigation to determine the optimal cortical target for MCS. The
MCS electrode was sutured to the dura mater. After placement of the electrode, the electrode
was tunneled subcutaneously and connected with an internalized pulse generator (IPG) (Med-
tronic Versitrel and later Prime Advanced) that was implanted in the subclavian space or in a
subcutaneous abdominal pocket.
Data-analysis
An independent researcher (D.H.), who was blinded to the stimulation conditions, investi-
gated the patient records in this observational study. Only patients who were treated in accor-
dance to the aforementioned treatment protocol and with a minimal follow-up of three years
in whom the effect of MCS, occurrence of complications, daily intake of medication and
change in quality of life was complete, were analyzed.
Ethical statement registration of clinical trial and reporting
This observational study was performed under the approval of the medical ethical committee
of the region Arnhem–Nijmegen. All patients, after extensive pre-operative information, gave
written informed consent due to the experimental nature of this treatment at that time. This
clinical trial was not registered in 2003 due to the fact that, in The Netherlands, MCS was not
an experimental method at that moment. The authors confirm that all ongoing and related tri-
als for this intervention are registered (ClinicalTrials.gov Identifier: NCT03189823). The
TREND Statement Checklist was added to this paper in order to contribute to the standardiza-
tion of the reporting of non-randomized trials (S1 File).
Assessment
Pain is a complex, subjective and multidimensional phenomenon that is difficult to measure
by unidimensional pain scores only. Apart from the visual analog scale (VAS), the intake of
pain medication is thought to be a valid tool of measuring pain relief[35, 36]. Adding analgesic
drug intake as an outcome parameter could provide a more realistic assessment of long-term
benefits of MCS[37]. Five outcome variables were examined: (1) the amount of pain relief,
measured by the mean difference between VAS score pre-operatively and the VAS score dur-
ing the follow-up (1 month, 6 months, 1 year, and 3 years after implantation of the MCS elec-
trodes); (2) the change in the drug regimen of all patients per day; (3) interference of pain with
quality of life (QoL); (4) adverse events (infection, bleeding, hardware removal, temporary sei-
zures, and battery dysfunction); and (5) the correlation between stimulation parameters and
the pain relief per patient. Pain relief was divided into three categories[38]. A good pain relief,
level 1, was defined as a VAS reduction of 70–100%. Reduction of pain according to a VAS
scores change between 40% and 69% was defined as satisfactory (level 2), while a minimal pain
relief was defined as a reduction of 40% on the VAS scores. A clinical relevant pain relief
was defined as 40% reduction of pain (levels 1 and 2)[38, 39]. The use of medication was
monitored using the electronic patient record during follow-up. The medication quantifica-
tion scale (MQS) was used in order to quantify medication use and was calculated for each
drug by multiplying the dosage levels by their respective detriment weight[40]. The dosage
levels (0–6) were based on the recommended daily dosage range as described by Masters
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Steedman et al.[41]. These scores are summed to provide a quantitative index of total drug
intake suitable for statistical analysis. Interference of pain with quality of life (QoL) was mea-
sured before and after (> 1 year) MCS with use of the Quality of Life Index (QLI), based on
the Dutch version of the McGill pain questionnaire (MPQ-DLV)[42, 43]. The occurrence of
complications was documented as well. Apart from biological complications (eg. bleeding,
infection), the removal of the hardware due to a minimal effect was evaluated as well. To deter-
mine whether there was a correlation between the used stimulation parameters and the pain
relief, the used stimulation parameters (intensities [V], pulse widths [μs], and frequencies
[Hz]) were reviewed.
Statistical analysis
IBM SPSS Statistics version 22 was used for statistical analyses of the retrieved data (IBM Corp.
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). The
differences in VAS-scores MQS-scores and QoL-indices over time were analyzed using a
mixed model analysis. To determine differences between groups in MQS-scores, the Mann-
Whitney U test was used. In order to correlate the applied stimulation parameters, the Spear-
man rank correlation coefficient was conducted. To determine the complication rate across
time, a Poisson regression analysis was conducted. Values are represented as mean ± standard
deviation (minimum- maximum). Statistical tests were two sided and with a significance level
of P< 0.05 (S2 and S3 Files).
Results
Eighteen patients were included (Fig 1). The mean age was 59.0 ± 7.3 years (41–72 years), and
10 of them were females. The mean duration of pain was 7.7 ± 6.1 years (2–26 years). Tables 1
and 2 summarize the baseline surgery-related characteristics and the outcomes of MCS and
the complications due to surgery. The complete, anonymized database has been made avail-
able; see S1 Database).
Pain relief according to VAS scores
The mean pre-operative VAS was 89.4 ± 11.2. A mean VAS score of 59.2 ± 21.4 was observed
after 1 month (P< 0.0001). A clinical relevant pain relief (level 1 and 2) was observed in 38.9%
of the patients after 1 month. After 6 months, a mean VAS score of 58.3± 20.9 was observed
(P< 0.0001). After 1 year, the most optimal results were observed with a clinical relevant pain
relief in 44.4% of the patients and a mean VAS score of 56.1 ± 29.6 (P< 0.0001). After 3 years
of MCS, a mean VAS score of 53.1 ± 25.0 was observed (P< 0.0001).
A clinical relevant pain relief was observed in 38.9% of the described population after 3
years of follow-up and a mean VAS reduction of 36.4 points. This indicates seven responders
(R) to MCS and eleven non-responding patients (NR). All responders to MCS (n = 7) showed
to be suffering pain due to lesions in the central nervous system. In the non-responder group
(n = 11), central lesions were seen in three cases. With regard to all the patients with central
pain lesions (n = 10), a clinical relevant pain relief was observed in 70% of the cases and a
mean VAS reduction of 54.5% ± 23.9 could be observed. All the patients with a peripheral
lesion (n = 8) showed a mean VAS reduction of 16.7% ± 10.0. This indicated a significant dif-
ference in response to MCS (P = 0.002). As many of the patients suffered from orofacial pain,
this group was also reviewed separately. When the orofacial pain candidates and the site of the
lesion were reviewed, MCS showed to have a significant favorable outcome (P = 0.003) in the
treatment of proximal (or central) lesions (Table 3).
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Modifications in drug regimens
At baseline, 16 patients used pain medication. Fig 2 discloses the cumulative daily intake of
pain medication before and after MCS. A total reduction of 24% is shown. The daily intake of
opioids decreased to zero after MCS. MQS scores per patient before and after MCS are repre-
sented in Table 4. The median MQS score before MCS was 6.6, whereas the median MQS
score after MCS was 5.4, which did not reach statistical significance (P = 0.210). Responders
showed a median MQS score before and after MCS of 6.3 and 5.4, respectively, ranging from 0
to 14.1 before MCS and 0 to 20.7 after MCS (z = -0.734; P = 0.463). The non-responders had a
Fig 1. CONSORT 2010 flow diagram.
https://doi.org/10.1371/journal.pone.0191774.g001
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median MQS score of 11.5 and 5.4 before and after MCS, respectively, ranging from 5.4 to 26.1
before and 0 to 15.6 after MCS (z = -2.549; P = 0.011).
Quality of life index
The QoL-index was used in order to measure the impact of MCS on the pain-related quality of
life. QoL-indices were retained from thirteen patients. Three patients were lost during follow-
up of QoL due to recurrent infections and removal and re-implantation of MCS electrodes
(#1;2;17). The mean pre- and postoperative QoL-index showed to be 11.9 ± 3.5 and 7.7 ± 4.4,
indicating a significant improvement in QoL (P = 0.007). Responders and non-responders to
MCS did not show a significant different preoperative QoL-index (P = 0.249), whereas the
postoperative QoL-index showed significant differences in favor of the group responders
(P = 0.002).
Table 1. Demographic characteristics.
Sex/ age,
years
Cause Diagnosis Groupa Location of pain Duration of pain,
years
Sensory
loss
Allodynia Motor
weakness
Timing Pain descriptors
1 M/58 WS PSP A Right hemiface and left
hemibody
3 Yes Yes No Continuous Aching; Pricking
2 M/65 CVA PSP A Left hemibody 4 Yes Yes No Continuous Burning
3 M/61 WS PSP A Left hemiface 16 Yes Yes Yes Continuous Burning
4 F/67 CVA PSP A Left hemiface and
tongue
26 Yes Yes Yes Continuous Aching
5 M/61 TN TN1 A Left hemiface 13 Yes No No Paroxysmal Electric; Sharp;
Shooting
6 M/56 TN TN1 A Left hemiface 12 Yes Yes Yes Paroxysmal Aching; Electric;
Sharp
7 M/57 TN TN2 A Left hemiface 10 Yes Yes No Continuous Aching; Electric;
Sharp
8 F/50 TS PSP B Left hemibody 6 Yes Yes No Continuous Dull; Throbbing
9 M/59 CVA PSP B Left hemiface and left
hand
8 Yes Yes Yes Continous Burning
10 F/52 CVA PSP B Right hemiface and
right arm
2 Yes Yes Yes Continous Burning
11 F/41 X PIFP B Left hemiface 9 No Yes No Continuous Aching; Dull;
Nagging
12 F/63 X PIFP B Left hemiface 4 No Yes No Continuous Dull; Nagging
13 F/63 ESG CPSP B Left hemiface and left
tongue
5 Yes Yes No Paroxysmal Electric; Shooting
14 F/72 IONP BMS B Right tongue and oral
cavity
6 No Yes No Continuous Burning
15 F/54 MF TNP B Left hemiface 6 Yes Yes No Continuous Burning; Electrical
16 F/61 IONP BMS B Intraoral mucosa 2 No No No Continuous Burning
17 F/54 AMP PhP B Phantom limb pain of
right arm
3 N/A N/A N/A Continuous Burning;
Cramping
18 M/68 BPA AvP B Left arm 3 Yes No Yes Continuous Burning; Shooting
a Group A, responding patients; group B, non-responding patients
AMP, amputation; AvP, avulsion pain; BMS, burning mouth syndrome; BPA, brachial plexus avulsion; CPSP: Chronic post-surgical pain; CVA, cerebrovascular
accident; ESG, extirpation of the submandibular gland; F, female; IONP, intraoral neuropathic pain; M, male; MCS, motor cortex stimulation; MF, mandibular fracture;
PSP, post-stroke pain; PIFP, persistent idiopathic facial pain; TN1, trigeminal neuralgia type 1 (>50% episodic); TN1, trigeminal neuralgia type 1 (>50% constant);
TNP, trigeminal neuropathic pain; TS, thalamus syndrome; VAS, visual analog scale; WS, Wallenberg syndrome; X, unknown
https://doi.org/10.1371/journal.pone.0191774.t001
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Complications
Complications occurred in nine patients (50%). In three patients, an infection of the electrode
and the extension wire occurred and the electrodes were removed (#1;2;17). One patient (#10)
experienced a short-lasting, intra-operative epileptic seizure during intra-operative stimulation
of the motor cortex. One patient suffered from an IPG hardware malfunctioning (#13). In four
cases, the system was explanted on request of the patient due to an unsatisfactory pain relief
(#8;10;11;16). After it was observed that some patients suffered from local pain after implant-
ing the IPG in the subclavian area, the IPG implantation area was switched to the subcutane-
ous abdominal space (#3;5;7). The complication rate across time showed to be 0.16 events per
person years (95%-Confidence interval = 0.07–0.34).
Stimulation parameters
The intensity of the stimulation varied between 1.5 V and 5.0 V. The frequencies ranged
from 40 Hz to 60 Hz, and the pulse width ranged from 60 μs to 120 μs (Table 4). No corre-
lation between the applied intensities or pulse widths and the pain relief at last follow-up
could be observed (Spearman correlation = 0.1, P = 0.692, and Spearman correlation =
0.045, P = 0.860, respectively). A significant correlation (P = 0.035), however, was observed
between the applied frequencies and the pain relief at the last follow-up (Spearman correla-
tion = 0.498).
Table 2. VAS scores and complication registration.
Sex/ age,
years
Groupa VAS
before
MCS
VAS 1
month
Pain
relief%
VAS 6
months
Pain
relief%
VAS 1
year
Pain
relief%
VAS 3
years
Pain
relief%
Level of pain
controlb
Device
removed
Complications
1 M/58 A 50–80 30 54 30 54 30 54 30 54 2 Yes Infection
2 M/65 A 90 20–30 72 30 67 40 56 40 56 2 Yes Infection
3 M/61 A 100 60–70 35 60–70 35 40–70 45 40 60 2 No
4 F/67 A 100 20 80 20 80 40 60 30 70 1 No
5 M/61 A 80 30 63 30 63 0 100 0 100 1 No
6 M/56 A 90 40 56 40 56 30 67 30 67 2 No
7 M/57 A 100 60 40 50 50 50 50 40 60 2 No Temporary seizures
8 F/50 B 60–90 60 20 60 20 50 33 60 20 3 Yesc
9 M/59 B 80 60 25 50 38 60 25 50 38 3 No
10 F/52 B 100 80–100 10 80 20 60 40 80 20 3 Yesc
11 F/41 B 100 80 20 70 30 60–80 30 80 20 3 Yesc
12 F/63 B 80 40–80 25 40–80 25 40–80 25 40–80 25 3 No
13 F/63 B 100 10–20 85 10–20 85 70–80 25 70–80 25 3 No IPG hardware
malfunctioning
14 F/72 B 80 60–80 13 80 0 70 12.5 80 0 3 No
15 F/54 B 100 80 20 80 20 80 20 80–100 10 3 No
16 F/61 B 90 70 22 80 11 80 11 80 11 3 Yesc
17 F/54 B 80 70 12.5 70 12.5 70–80 7.5 70 12.5 3 Yes Infection
18 M/68 B 100 70 30 70 30 70 30 70 30 3 No
a Group A, responding patients; group B, non-responding patients
b Level 1, 70–100%; level 2, 40–69%; level 3, 0–39%.
c Device removed due of minimal effect according to patients perspective.
F, female; IPG, implantable pulse generator; M, male
https://doi.org/10.1371/journal.pone.0191774.t002
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Table 3. Characteristics of the orofacial pain patient group.
Sex/
age,
years
Painful
area
L/R Diagnosis Groupa Period
of pain,
years
Sensory
loss
Allodynia Motor
deficit
History of
interventions/
problems with
regard to the
orofacial pain
syndrome
Pain
relief,
(%, after
3 years
of MCS
Level of
pain
controlb
Changes in
MQSc
Changes in
QLId
1 M/58 Hemiface
and
hemibody
R
+L
PSP A 3 Yes Yes No Rhinosinal surgery;
sweet procedure
54 2 Diminished N/A
3 M/61 Hemiface R
+L
PSP A 16 Yes No No Sweet procedure;
thermolesion; ITB
therapy
60 2 Diminished Diminished
4 F/67 Hemiface L PSP A 26 Yes Yes Yes TENS; multiple
PEA injections;
Dandy procedure
70 1 Diminished Diminished
5 M/61 Hemiface L TN1 A 13 Yes Yes Yes TENS; PEA
injection; Sweet
procedure; 2x
vascular
decompression;
stereotactic
radiosurgery
100 1 Diminished Diminished
6 M/56 Hemiface L TN1 A 12 Yes Yes Yes 3x stereotactic
radiosurgery
67 2 No change Diminished
7 M/57 Hemiface L TN2 A 10 Yes Yes No Glycerol injection;
vascular
decompression;
stereotactic
radiosurgery
60 2 Diminished Diminished
9 M/59 Hemiface
and
hemibody
L PSP B 8 Yes Yes Yes N/A 38 3 Diminished Diminished
10 F/52 Hemiface
and
hemibody
R PSP B 2 Yes Yes Yes N/A 20 3 Increased No change
11 F/41 Hemiface L PIFP B 9 No Yes No Vascular
decompression;
rhinosinal surgery;
mandibular surgery;
5x Sweet procedure
20 3 Diminished Diminished
12 F/63 Hemiface L PIFP B 4 Yes Yes No Vascular
decompression;
sinus surgery
25 3 Increased No change
13 F/63 Hemiface L CPSP B 5 Yes Yes Yes Submandibular
surgery; PEMF; 3x
RF lesion
25 3 Increased Diminished
14 F/72 Intraoral R BMS B 6 No Yes No Malfitting dentures;
vascular
decompression of n.
V, n. IX and n. X
0 3 Increased Diminished
15 F/54 Hemiface L TNP B 6 Yes Yes No Vascular
decompression;
stereotactic
radiosurgery,
10 3 Diminished Diminished
(Continued)
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Discussion
Effect of MCS
This paper reports that the positive effects of MCS are associated with a decrease in pain scores
(VAS), improved quality of life and a diminished consumption of pain medication. Various
reports in chronic pain management show that the improvement that patients experience after
MCS takes place in numerous domains. Therefore, the analgesic effects must be registered
using pain intensity scores, quality of life assessments and a medication intake score [44]. For
example, this study shows that, although some patients do not report a significant pain reduc-
tion, their pain medication diminished. This weaning of opioids can be the effect of MCS, but
it can also be causative as during follow-up, patients were screened for the effects and side-
effects of the analgesics they used. Some patients could gradually be weaned from opioids due
to inefficacy and bothersome side-effects. Therefore, as stated earlier, a single change in out-
come in these complex pain syndromes simplifies the quality of the treatment effect. The QLI
showed to be significantly decreased by MCS in all patients, which is an aspect that is not fre-
quently addressed in the literature on MCS.
Central vs. peripheral pain
As mentioned, a significant difference in response to MCS between the central and peripheral
pain patients was observed. This phenomenon could be the result of a hypothesized double
projection of body regions to the thalamus and the somatosensory cortical areas[45, 46]. If
both thalami get involved into nociceptic processing due to a peripheral lesion, MCS might
not be capable to provide a complete analgesic effect in this group. The significant difference
in response to MCS in orofacial pain could be the result of a recent review, hypothesizing a
double tract that conducts orofacial pain[47]. However, in general, classic trigeminal neuralgia
is not considered an etiology which is treatable by MCS. Due to the extensive history of inter-
ventions to provide pain relief, including glycerol- and palmitoylethanolamide injections,
Table 3. (Continued)
Sex/
age,
years
Painful
area
L/R Diagnosis Groupa Period
of pain,
years
Sensory
loss
Allodynia Motor
deficit
History of
interventions/
problems with
regard to the
orofacial pain
syndrome
Pain
relief,
(%, after
3 years
of MCS
Level of
pain
controlb
Changes in
MQSc
Changes in
QLId
16 F/61 Intraoral R
+L
BMS B 2 No No No 18x dental surgery 11 3 No change No change
a Group A, responding patients; group B, non-responding patients
b Level 1, 70–100%; level 2, 40–69%; level 3, 0–39%.
c Dimished, MQS after MCS<MQS before MCS (negative rank); Increased, MQS after MCS>MQS before MCS (positive rank); No change, MQS after MCS equal to
MQS before MCS (tie).
d Dimished, QLI after MCS<QLI before MCS (negative rank); Increased, QLI after MCS>QLI before MCS (positive rank); No change, QLI after MCS equal to QLI
before MCS (tie).
 In Wallenberg syndrome or infarction of brainstem and cerebellum often causes bilateral pain; (oro)facial pain will occur ipilateral to the side of the lesion; pain in the
body will occur contralateral to the side of the lesion
CPSP: Chronic post-surgical pain; F, female; ITB, intrathecal baclofen therapy; L/R, left or right; M, male; MCS, motor cortex stimulation; MQS, medication
quantification scale; N/A, not applicable/not available; PEA, palmitoylethanolamide injection; PEMF, pulsed electromagnetic field stimulation; PSP, post-stroke pain;
PIFP, persistent idiopathic facial pain; RF lesion, radiofrequent nerve lesion; TENS, transcutaneous electroneurostimulation; TN1, trigeminal neuralgia type 1 (>50%
episodic); TN1, trigeminal neuralgia type 1 (>50% constant); TNP, trigeminal neuropathic pain; AvP, avulsion pain; BMS, burning mouth syndrome
https://doi.org/10.1371/journal.pone.0191774.t003
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stereotactic radiosurgery, Sweet procedures and vascular decompressions, the diagnosis of a
classic trigeminal neuralgia can be discussed. All the aforementioned interventions possible
damage the trigeminal nerve, which would lead trigeminal neuropathic pain, instead of pain
caused by a classic trigeminal neuralgia. In short, the onset of the trigeminal neuralgias in all
these patients was most probably idiopathic but the chronic orofacial pain treated by MCS
probably resulted from sensory deafferentation due to various (Table 3). Possibly, the combi-
nation of a clear anatomical region with detectable changes on neuro-imaging, combined with
a relatively large somatotopic area to be stimulated, is key to these findings. However, classify-
ing this anatomical diagnosis in a mechanism-based way remains difficult.
Stimulation parameters and clinical effects
The various stimulation parameters (intensity, pulse width, frequency) in combination with
the anatomical position (e.g. distance dura-cerebral cortex) of the electrode and per-operative
neurophysiological measurements, all influence the effects of MCS[11]. Regarding the stimula-
tion parameters used, recent research shows a wide range of parameters[48]. By changing
these parameters in each individual case during follow-up and using the (subjective) patient’s
Fig 2. Differences in the cumulative, total intake of pain medication in milligram per day before and after MCS. GABA, gamma-aminobutyric acid; NSAID, non-
steroidal anti-inflammatory drug; MCS, motor cortex stimulation; SSNRI, selective serotonin and norepinephrine reuptake inhibitor.
https://doi.org/10.1371/journal.pone.0191774.g002
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response, it is considered that the optimal effect can be reached. Next to the electrical parame-
ters, the type of electrode and lead configuration are thought to be of great importance in the
achieved pain reduction[1, 29, 49–51]. No consensus on these matters has been achieved
although stimulation over the anterior bank of the central sulcus is frequently reported to pro-
vide the best analgesic effect, which can also temporarily be observed in some patients with
non-invasive, transcranial magnetic motor cortex stimulation[52]. The use of fMRI and intra-
operative cortical mapping as presented in this study seems to be a useful method of finding
the optimal target for MCS[53].
Strengths and limitations
All patients were seen by a team of anesthesiologist-pain specialists, neurosurgeons, and clini-
cal psychologists preceding the operation and during the treatment process. Since it is known
that an evaluation by the operator involved creates bias, the participation of an independent
observer adds to the strength of the results. The absence of a control group forms an important
Table 4. Stimulation parameters, medication quantification scales and analgesic effects per patient.
Diagnosis Groupa Pain relief,
%, after
3 years of
MCS
Level of pain
controlb
Intensity,
Vc
Frequency,
Hzc
Pulse
width, μsc
MQSpre MQSpost Changes in
MQSd
QLI
pre
QLI
post
Changes in
QLIe
1 PSP A 54 2 2 50 90 16.5 4.2 Diminished N/A N/A N/A
2 PSP A 56 2 1.5 50 80 5.4 5.4 No change N/A N/A N/A
3 PSP A 60 2 2.5 50 60 15.3 13.2 Diminished 9 7 Diminished
4 PSP A 70 1 2.5 60 60 6.3 4.2 Diminished 14 2 Diminished
5 TN1 A 100 1 3 50 60 8.2 0 Diminished 7 2 Diminished
6 TN1 A 67 2 4.5 40 90 0 0 No change 14 4 Diminished
7 TN2 A 60 2 4.5 50 120 6.3 4.8 Diminished 8 4 Diminished
8 PSP B 20 3 2.5 50 90 26.1 4.2 Diminished 7 1 Diminished
9 PSP B 38 3 3 50 60 14.1 4.2 Diminished 11 10 Diminished
10 PSP B 20 3 2.5 50 60 0 5.4 Increased 16 16 No change
11 PIFP B 20 3 4 50 60 11.5 8.4 Diminished 16 12 Diminished
12 PIFP B 25 3 5 50 90 6.3 6.9 Increased 13 13 No change
13 CPSP B 25 3 3 50 60 6.4 7.8 Increased 16 8 Diminished
14 TNP B 0 3 3 40 60 6.8 10.7 Increased 12 10 Diminished
15 TNP B 10 3 2 40 80 23.4 15.6 Diminished 11 10 Diminished
16 BMS B 11 3 3 40 90 5. 5.4 No change 8 8 No change
17 PhP B 12.5 3 2.5 50 60 6.3 12 Increased N/A N/A N/A
18 AvP B 30 3 3 50 60 24.6 14.2 Diminished 17 8 Diminished
a Group A, responding patients; group B, non-responding patients
b Level 1, 70–100%; level 2, 40–69%; level 3, 0–39%.
c Stimulation parameters that were reported at the last follow-up.
d Dimished, MQS after MCS<MQS before MCS (negative rank); Increased, MQS after MCS>MQS before MCS (positive rank); No change, MQS after MCS equal to
MQS before MCS (tie).
e Dimished, QLI after MCS<QLI before MCS (negative rank); Increased, QLI after MCS>QLI before MCS (positive rank); No change, QLI after MCS equal to QLI
before MCS (tie).
AvP, avulsion pain; BMS, burning mouth syndrome; BPAP, brachial plexus avulsion pain; CPSP: Chronic post surgical pain; Hz, Hertz; μs, microseconds; MCS, motor
cortex stimulation; MQS, medication quantification scale; MQSpost, medication quantification scale following MCS; MQSpre, medication quantification scale before
MCS; N/A, Not available; PIFP, persistent idiopathic facial pain; PSP, post-stroke pain; QoL-index pre, Quality of life index before MCS; QoL-index post, Quality of life
index following MCS; TN1, trigeminal neuralgia type 1 (>50% episodic); TN1, trigeminal neuralgia type 1 (>50% constant); TNP, trigeminal neuropathic pain
https://doi.org/10.1371/journal.pone.0191774.t004
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limitation of this study. Nevertheless, this lack of a control group can be explained by the unac-
ceptable safety aspects of performing a sham surgical intervention and limited trustworthiness
of a control group in MCS studies. A double blinded on/off-phase trial could be a valuable
addition with regard to the lack of a control group. Second, as over the years new insights in
neurophysiological features of chronic pain and MCS were gained, important diagnostic steps
were not included in this protocol. For example, Rasche and Tronnier suggested that a double-
blinded test trial with an external stimulation device could identify non-responders and pla-
cebo responders, hence improving the results of MCS[5]. They also perform a trial with an
externalized epidural lead, although the authors think that the effects of MCS can take for
months to occur, which makes an externalized epidural lead hazardous due to high risk of
infections[5]. Other studies suggest that the efficacy of MCS relies on the number of available
opioid receptors in the brain[14, 15]. As both the double-blinded test trial with transcranial
stimulation and the pre-operative (11)C-diprenorphine positron emission tomography scan
were not widely accessible exploration possibilities, possible non-responders were not recog-
nized. However, these sophisticated techniques are still not widely available.
Nowadays, all ongoing and related trials for MCS must be registered, but just like this
study, some studies might not have been registered as this was not common practice at that
time. For studies that were started at the time when the registration of trials started and of
which the results currently can be presented, this might offer a problem. Strict adherence to
this policy might introduce loss of a huge amount of valuable data that could be used to raise
questions and help to develop or refute treatments.
Furthermore, more sophisticated imaging techniques such as diffusion tensor imaging, at
higher resolutions, could contribute to our understanding of nociceptive pathways in humans.
For example, as this report shows, different forms of orofacial pain, conducted by different
nociceptive pathways (i.e. central vs. peripheral orofacial pain) respond differently to MCS. A
stricter guideline or protocol of selecting and treating patients with MCS seems to be of great
importance in order to optimize the efficacy.
Conclusion
MCS shows to be promising with regard to the long-term effects in patients suffering from
chronic, intractable, neuropathic pain, especially in patients who suffer from pain, caused by a
central lesion. Optimizing the pre-operative diagnostic procedure and careful patient selection
can increase the success rate of MCS. Second, the effect of MCS should not only be evaluated
by measuring pain scores alone, but also by alterations in daily intake of pain medication and
quality of life.
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